会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • Adenosine A2a receptor antagonists
    • 腺苷A2a受体拮抗剂
    • US06653315B2
    • 2003-11-25
    • US10269754
    • 2002-10-11
    • Deen TulshianLisa S. SilvermanJulius J. MatasiEugenia Y. KiselgofJohn P. Caldwell
    • Deen TulshianLisa S. SilvermanJulius J. MatasiEugenia Y. KiselgofJohn P. Caldwell
    • C07D48714
    • C07D487/14A61K31/198A61K31/505A61K45/06Y02P20/582A61K2300/00
    • Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl or heteroaryl, cycloalkenyl, —C(═CH2)CH3, —C≡C—CH3, —CH═C(CH3)2, X is alkylene, —C(O)CH2— or —C(O)N(R2)CH2—; Y is —N(R2)CH2CH2N(R3)—, —OCH2CH2N(R2)—, —O—, —S—, —CH2S—, —(CH2)2—N(R2)—, or optionally substituted divalent heteroaryl, piperidinyl or piperazinyl; and Z is optionally substituted phenyl, phenylalkyl or heteroaryl, diphenylmethyl or R6—C(O)—; or when Y is Z is also R6—SO2—, R7—N(R8)—C(O)—, R7—N(R8)—C(S)— or R6OC(O)—; or when Y is 4-piperidinyl, Z can be phenylamino or pyridylamino; or Z and Y together are substituted piperidinyl, substituted pyrrolidinyl or substituted phenyl; R14 is H, halogen or optionally substituted alkyl; and Q, Q1, m, n, R2, R3, R4, R6, R7 and R8 are as defined in the specification are disclosed, their use in the treatment of Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.
    • 具有结构式I的化合物或其药学上可接受的盐,其中R是任选取代的苯基或杂芳基,环烯基,-C(= CH 2)CH 3,-C = C-CH 3,-CH = C(CH 3)2,X是亚烷基, -C(O)CH 2 - 或-C(O)N(R 2)CH 2 - ; Y是-N(R 2)CH 2 CH 2 N(R 3) - ,-OCH 2 CH 2 N(R 2) - , - O - , - S - , - CH 2 S - , - (CH 2)2 -N(R 2) - 或任选取代的二价杂芳基,哌啶基或哌嗪基; 和Z是任选取代的苯基,苯基烷基或杂芳基,二苯基甲基或R 6 -C(O) - ;或当Y是Z时也是R 6 -SO 2 - ,R 7 -N(R 8) C(O) - ,R 7 -N(R 8)-C(S) - 或R 6 OC(O) - ;或当Y是4-哌啶基时,Z可以是苯基氨基或吡啶基氨基; 或Z和Y一起是取代的哌啶基,取代的吡咯烷基或取代的苯基; R 14是H,卤素或任选取代的烷基; 和Q,Q 1,m,n,R 2,R 3,R 4,R 6,R 7和R 8如说明书中所定义,它们 用于治疗帕金森氏病,单独或与其他治疗帕金森病的药物组合,以及包含它们的药物组合物。